Novartis gains U.S. approval for delayed MS drug

loading...


Novartis gains U.S. approval for delayed MS drug
ZURICH (Reuters) – Novartis’s Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.


Source: Health And Fitness

Reply

Pin It on Pinterest

Shares
Share This
loading...